drugset / Trial / NCT00337155
BAY88-8223, Dose Finding Study in Patients With HRPC
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223, Alpharadin, in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
Timeline
- Start
- 2006-05
- Primary completion
- 2008-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Radium-223 dichloride | Other / unclassified | 0.025 mbq/kg | Other |
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Other |
| Subject | Radium-223 dichloride | Other / unclassified | 0.08 mbq/kg | Other |